KR20230116799A - 신규 이미다졸 아세틸렌 유도체 - Google Patents

신규 이미다졸 아세틸렌 유도체 Download PDF

Info

Publication number
KR20230116799A
KR20230116799A KR1020237018340A KR20237018340A KR20230116799A KR 20230116799 A KR20230116799 A KR 20230116799A KR 1020237018340 A KR1020237018340 A KR 1020237018340A KR 20237018340 A KR20237018340 A KR 20237018340A KR 20230116799 A KR20230116799 A KR 20230116799A
Authority
KR
South Korea
Prior art keywords
methyl
imidazol
thiazol
indazol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018340A
Other languages
English (en)
Korean (ko)
Inventor
코시모 돌렌트
아닉 괴글러
데이비드 스티븐 휴윙스
게오르크 얘슈케
잔더 울리케 오브스트
안토니오 리치
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20230116799A publication Critical patent/KR20230116799A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237018340A 2020-12-01 2021-11-29 신규 이미다졸 아세틸렌 유도체 Pending KR20230116799A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
EP20210859.3 2020-12-01
PCT/EP2021/083279 WO2022117477A1 (en) 2020-12-01 2021-11-29 New indazole acetylene derivatives

Publications (1)

Publication Number Publication Date
KR20230116799A true KR20230116799A (ko) 2023-08-04

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018340A Pending KR20230116799A (ko) 2020-12-01 2021-11-29 신규 이미다졸 아세틸렌 유도체

Country Status (15)

Country Link
US (1) US20240002390A1 (https=)
EP (1) EP4255908A1 (https=)
JP (1) JP7840327B2 (https=)
KR (1) KR20230116799A (https=)
CN (1) CN116490182A (https=)
AR (1) AR124170A1 (https=)
AU (1) AU2021393722A1 (https=)
CA (1) CA3197659A1 (https=)
CL (1) CL2023001440A1 (https=)
CO (1) CO2023006912A2 (https=)
CR (1) CR20230218A (https=)
IL (1) IL303064A (https=)
MX (1) MX2023006176A (https=)
PE (1) PE20240099A1 (https=)
WO (1) WO2022117477A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008049B (zh) 2019-06-21 2024-07-05 豪夫迈·罗氏有限公司 用于癌症治疗的egfr抑制剂
JP7840324B2 (ja) 2020-12-01 2026-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
JP2025516543A (ja) * 2022-05-13 2025-05-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのアロステリックおよびオルソステリックegfr阻害剤の組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
SG11202011818YA (en) * 2018-06-29 2020-12-30 Hoffmann La Roche Compounds
CN113993591A (zh) * 2019-06-21 2022-01-28 豪夫迈·罗氏有限公司 新egfr抑制剂

Also Published As

Publication number Publication date
CN116490182A (zh) 2023-07-25
US20240002390A1 (en) 2024-01-04
JP7840327B2 (ja) 2026-04-03
PE20240099A1 (es) 2024-01-18
CR20230218A (es) 2023-07-07
CA3197659A1 (en) 2022-06-09
EP4255908A1 (en) 2023-10-11
JP2023550902A (ja) 2023-12-06
WO2022117477A1 (en) 2022-06-09
TW202237611A (zh) 2022-10-01
AR124170A1 (es) 2023-02-22
CL2023001440A1 (es) 2023-12-01
CO2023006912A2 (es) 2023-06-09
MX2023006176A (es) 2023-06-08
AU2021393722A1 (en) 2023-04-13
IL303064A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
TWI833773B (zh) 化合物
WO2024041606A1 (zh) 具有抗kras突变肿瘤活性的化合物
EP3986895A1 (en) Egfr inhibitors for the treatment of cancer
CA3139171A1 (en) New egfr inhibitors
JP7840324B2 (ja) 新規インダゾール誘導体
KR20230116799A (ko) 신규 이미다졸 아세틸렌 유도체
EP4076664B1 (en) Egfr inhibitors
TW202313606A (zh) 取代的苯基-1h-吡咯并[2,3-c]吡啶衍生物
US20160152599A1 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
JP7798887B2 (ja) 新規インダゾール誘導体
KR20250012058A (ko) 신규 이미다졸 유도체
RU2853003C1 (ru) Новые индазолацетиленовые производные
WO2023209090A1 (en) Bicyclic heteroaromatic compounds and their application in the treatment of cancer
TWI915460B (zh) 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途
HK40094041A (zh) 新的吲唑乙炔衍生物
HK40092553A (zh) 新的吲唑衍生物
HK40115444A (zh) 新的吲唑衍生物
TW202542138A (zh) 與含patatin樣磷脂酶結構域蛋白3IM結合的化合物及其用於治療肝病之用途
HK40092556A (zh) 新的吲唑衍生物
HK40067220A (zh) 新egfr抑制剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230531

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241128

Comment text: Request for Examination of Application